SNY, TEVA Stocks Jump on Encouraging Data From IBD Drug Study

Sanofi (SNY) and partner Teva Pharmaceuticals (TEVA) announced positive data from the phase IIb RELIEVE UCCD study on their investigational anti-TL1A therapy, duvakitug (formerly TEV’574), for the treatment of Ulcerative Colitis (UC) and Crohn's disease (CD), the two main types of inflammatory bowel disease (IBD). The study met its primary endpoints for both diseases.Treatment With SNY-TEVA Drug Exhibits Best-in-Class PotentialIn the UC group, 36.2% of patients who received a low dose of the drug and 47.8% ...